Advertisement

Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 600x60px
Document › Details

CRISPR Therapeutics AG. (11/10/14). "Press Release: CRISPR Therapeutics Founding Scientist, Emmanuelle Charpentier Awarded 2015 Breakthrough Prize in Life Sciences". Basel.

Organisations Organisation Helmholtz-Zentrum für Infektionsforschung GmbH (HZI)
  Group Helmholtz-Gemeinschaft (HGF) (Group)
  Organisation 2 Umeå University
Products Product CRISPR gene editing technology
  Product 2 genomic technology
Persons Person Charpentier, Emmanuelle (Helmholtz 201412 Professor at HZI)
  Person 2 Novak, Rodger (CRISPR Therapeutics 201404 CEO before Sanofi + Nabriva GmbH)
     


CRISPR Therapeutics, a biopharmaceutical company focused on the gene-editing technology CRISPR-Cas9, today announced that Dr Emmanuelle Charpentier, a co-founder and advisor to the Company, has been awarded the 2015 Breakthrough Prize in Life Sciences. Dr Charpentier, head of the Regulation in Infection Biology department at the Helmholtz-Zentrum für Infektionsforschung (Helmholtz Centre for Infection Research) in Braunschweig, Germany, was honored for her pioneering work in the development of the CRISPR-Cas9 genome-editing tool.

CRISPR-Cas9 is an innovative gene-editing technology that can be used to edit the genomes of organisms directly with surgical precision. It can be used to specifically target a diseased gene and either delete or correct it. Dr Charpentier co-invented the CRISPR-Cas9 technology while working at Umea University in Sweden.

“CRISPR-Cas9 has the potential to become an incredibly powerful tool for efficient and accurate genome editing. I believe that CRISPR Therapeutics, a company that I helped found and to which I licensed my rights to the CRISPR-Cas9 foundational intellectual property, is well positioned to be in the forefront of clinical development based on this technology,” commented Dr Charpentier.

Dr Rodger Novak, chief executive officer of CRISPR Therapeutics added, “CRISPR-Cas9 is a transformative new technology that will have a significant impact on drug development and will open up the potential to cure serious human genetic diseases. We are thrilled to be working closely with one of the leading CRISPR-Cas9 researchers and co-inventor of the technology and extend our congratulations to Emmanuelle on her well-deserved recognition for the discovery.”


ABOUT THE BREAKTHROUGH PRIZE IN LIFE SCIENCES

The Breakthrough Prize is funded by internet entrepreneurs: Mark Zuckerberg and Priscilla Chan of Facebook; Sergey Brin of Google; entrepreneur and venture capitalist Yuri Milner; and Anne Wojcicki, co-founder of 23andMe. The $3 million Prize recognizes researchers, such as Dr Charpentier who are advancing research that extends human life and cures deadly diseases. The Breakthrough Prize in Life Sciences Foundation is a not-for-profit corporation dedicated to advancing research, celebrating scientists and generating excitement about the pursuit of science as a career. For more information, please visit http://breakthroughprize.org.


ABOUT CRISPR THERAPEUTICS

CRISPR Therapeutics is a Swiss biopharmaceutical company created to translate CRISPR-Cas9, an innovative gene-editing technology, into transformative medicines for serious human genetic diseases. CRISPR Therapeutics has rights to develop therapeutics based on an exclusive license to the foundational CRISPR-Cas9 intellectual property. The Company’s vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. For more information, please visit www.crisprtx.com.


CONTACTS

CRISPR Therapeutics:
Shaun Foy
Email: info@crisprtx.com

Media:
Aline Schimmel
Email: aschimmel@scientapr.com

   
Record changed: 2016-03-22

Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px

More documents for Helmholtz-Gemeinschaft (HGF) (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Sacura e.tract software 2017 600x60px wptb




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 120x180px Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 120x240px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture Sacura e.tract software 2017 120x240px wpetmf Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px